Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus
Theralase(R) Lists Warrants on the TSXV
Theralase(R) Releases Q1 2026 Financial Statements
Theralase(R) Closes C$4.8 Million Offering
Theralase Technologies Inc. (TLT:CA) Q4 2025 Earnings Call Transcript
Theralase(R) Announces $4 Million Brokered LIFE Offering
Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study
Theralase(R) Closes $CAN 2.66 Million Financing
Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus
Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer
Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy
Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting
Theralase(R) Provides Update on Bladder Cancer Clinical Study
Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study
Ferring Pharmaceuticals and Theralase® Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer
Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer
Theralase(R) Closes $1.3 M Non-Brokered Private Placement
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
Theralase(R) Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Theralase(R) Investor Conference Call Reminder
Theralase Technologies (CVE:TLT) Shares Up 2.4% – Here’s What Happened
Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus
Theralase(R) Extends Warrants
Theralase(R) Releases 2Q2025 Financial Statements
Theralase(R) Closes Non-Brokered Private Placement
Theralase(R) Extends Warrants
Theralase(R) Closes Non-Brokered Private Placement
Theralase Completes Annual General and Special Meeting
Theralase Technologies Inc. (TLTFF) Q1 2025 Earnings Call Transcript
Theralase Annual General Meeting
CORRECTION FROM SOURCE: Theralase to Present Groundbreaking Research at ASTRO 2025
Theralase to Present Groundbreaking Research at ASTRO 2025
Theralase Provides Corporate Update
Theralase Clinical Data Presented at Canadian Bladder Cancer Forum and American Urological Association
Theralase Discovers New Mechanism of Action of Lead Drug
Theralase(R) Closes Non-Brokered Private Placement
Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments
Ruvidar Demonstrates 7 Year Complete Response
Ruvidar Effective in the Treatment of Herpes
Theralase Technologies Inc. (TLTFF) Q4 2024 Earnings Call Transcript
Theralase(R) Releases 2024 Annual Financial Statements
Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma
CORRECTING AND REPLACING: Theralase(R) Demonstrates Effective Treatment of Herpes
Theralase(R) Demonstrates Effective Treatment of Herpes
Theralase(R) Releases Latest Research on Inactivation of Herpes Simplex Viruses
Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting
Theralase(R) Launches Three New Clinical Study Sites in USA